CLINICAL_TRIALS
trial_result
· 2024-09-24
Clinical Trial Update: A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis [Phase 2]
Summary
Phase 2 trial evaluating subcutaneous lirentelimab (AK002) for atopic dermatitis was terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Allakos Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2024-09-24